Abeona End Period Cash Flow from 2010 to 2024

ABEO Stock  USD 5.98  0.06  1.01%   
Abeona Therapeutics End Period Cash Flow yearly trend continues to be very stable with very little volatility. End Period Cash Flow is likely to grow to about 20.6 M this year. During the period from 2010 to 2024, Abeona Therapeutics End Period Cash Flow quarterly data regression pattern had sample variance of 1977.9 T and median of  14,811,000. View All Fundamentals
 
End Period Cash Flow  
First Reported
1995-12-31
Previous Quarter
34.8 M
Current Value
16.1 M
Quarterly Volatility
25.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Abeona Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abeona Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 397.1 K or Selling General Administrative of 18.1 M, as well as many indicators such as Price To Sales Ratio of 29.07, Dividend Yield of 1.6 K or PTB Ratio of 7.59. Abeona financial statements analysis is a perfect complement when working with Abeona Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Abeona Therapeutics Correlation against competitors.
To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.

Latest Abeona Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Abeona Therapeutics over the last few years. It is Abeona Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Abeona Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Pretty Stable
   End Period Cash Flow   
       Timeline  

Abeona End Period Cash Flow Regression Statistics

Arithmetic Mean34,386,116
Geometric Mean12,221,095
Coefficient Of Variation129.34
Mean Deviation32,572,856
Median14,811,000
Standard Deviation44,473,653
Sample Variance1977.9T
Range137.4M
R-Value0.20
Mean Square Error2041.9T
R-Squared0.04
Significance0.47
Slope2,023,194
Total Sum of Squares27690.7T

Abeona End Period Cash Flow History

202420.6 M
202314.8 M
202214.6 M
202138.8 M
202013.6 M
2019130.4 M
201819.3 M

About Abeona Therapeutics Financial Statements

Abeona Therapeutics investors utilize fundamental indicators, such as End Period Cash Flow, to predict how Abeona Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
End Period Cash Flow14.8 M20.6 M

Pair Trading with Abeona Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abeona Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abeona Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Abeona Stock

  0.74FLGC Flora Growth CorpPairCorr

Moving against Abeona Stock

  0.48PTN Palatin TechnologiesPairCorr
The ability to find closely correlated positions to Abeona Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abeona Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abeona Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abeona Therapeutics to buy it.
The correlation of Abeona Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abeona Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abeona Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abeona Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Abeona Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Abeona Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abeona Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abeona Therapeutics Stock:
Check out the analysis of Abeona Therapeutics Correlation against competitors.
To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.05)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.38)
Return On Equity
(1.27)
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.